Introduction {#sec1}
============

Degenerative aortic stenosis (AS) is currently the most common acquired valvular heart disease (VHD), and the third cardiovascular disease in the population of developed countries. Due to the observed aging of society the incidence of AS will steadily grow. An important issue is the early identification of patients with severe AS before it leads to impaired left ventricular (LV) systolic function \[[@cit0001]\]. Aortic valve stenosis leads to increased LV afterload resulting in an increase in LV wall stretch and wall hypertrophy of the LV as a compensatory mechanism to pressure overload \[[@cit0002]\]. Pressure overload lead to synthesis and release of natriuretic peptides, markers of LV wall stress \[[@cit0003]\]. Previous studies have shown elevated concentration of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in both patients with non-severe and those with severe AS. Moreover, in patients with AS NT-proBNP correlates with functional status assessed with New York Heart Association (NYHA) functional class and independently correlates with postoperative outcomes irrespective of clinical and echocardiographic factors \[[@cit0004]\].

Another biomarker of LV biomechanical overload is sST2 protein. ST2 is an IL-1 receptor family member with two isoforms: transmembrane (ST2L) and soluble (sST2). Interleukin-33 (IL-33) is a functional ligand for ST2L and has a cardioprotective effect against myocardial hypertrophy, fibrosis and apoptosis \[[@cit0005]\]. sST2 reduces the favorable effect of IL-33 because it acts as a decoy receptor \[[@cit0006]\].

It has been demonstrated that sST2 protein is a valuable prognostic biomarker in patients with myocardial infarction (MI), acute heart failure (AHF) and chronic heart failure (CHF) \[[@cit0007]--[@cit0009]\]. However, the role of sST2 protein in patients with AS is still unclear.

Aim {#sec2}
===

The aim of our study was to evaluate the utility of sST2 protein, NT-proBNP and selected clinical parameters in the assessment of degenerative AS severity in a population with preserved left ventricular ejection fraction (LVEF).

Material and methods {#sec3}
====================

Sixty-nine consecutive patients (mean age: 68.42 ±12.58 years, 55.07% male) with degenerative AS and preserved LVEF ≥ 45% hospitalized in the Cardiology Department to assess the severity of AS were prospectively included. All were symptomatic and clinically stable for at least 4 weeks in NYHA functional class II to ambulatory IV. Subjects with a concomitant significant disease of another valve, acute heart failure, acute coronary syndrome, autoimmune diseases and other inflammatory states were excluded.

At the time of study entry detailed demographic and clinical data (age, gender, body mass index (BMI), comorbidities) were collected and twelve-lead ECG (heart rate, QRS duration, QTc duration, Sokolow-Lyon index) was performed. At hospital admission the following standard laboratory tests were performed: hemoglobin, white blood cells, neutrophils, platelets, sodium level, creatinine level, estimated glomerular filtration rate, blood urea nitrogen, glucose, total cholesterol, low-density lipoproteins, high-density lipoproteins, triglycerides, high-sensitivity C-reactive protein (hs-CRP), high-sensitivity troponin T (hs-TnT) and NT-proBNP.

At enrollment patients also underwent a complete transthoracic echocardiographic examination (TTE) and the following data were obtained: left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), end-diastolic interventricular septum thickness (IVSd), end-systolic interventricular septum thickness (IVSs), end-diastolic posterior wall thickness (PWd), and end-systolic posterior wall thickness (PWs). The LVEF was measured in the four- and two-chamber apical view by the Simpson method. Parameters of AS severity -- maximum jet velocity, mean transvalvular pressure gradient and aortic valve area (AVA) (calculated by the continuity equation) -- were measured using the Doppler method in TTE. All examinations were performed by experienced echocardiographers as recommended by the European Society of Echocardiography.

According to aortic valve area patients were divided into two subgroups: severe (AVA \< 1.0 cm^2^) and non-severe AS (AVA ≥ 1.0 cm^2^).

At enrollment blood samples for sST2 were obtained by venipuncture and were collected into EDTA vacuum tubes. Immediately after collection the samples were centrifuged and we separated the plasma to a new Eppendorf tube. After separation the plasma was frozen at --76°C. Concentrations of sST2 were measured using sandwich monoclonal enzyme-linked immunosorbent assay kits (Medical and Biological Laboratories, no. 7638, MA, USA). The longest time of storage of the plasma at --76°C was 12 month. All samples were measured in triplicate to assess the repeatability. The limit of detection (sensitivity) was 0.032 ng/ml and the upper limit was 4 ng/ml. Measurements were carried out in the Department of Medical Biotechnology at the Medical University of Lodz.

The study conforms with the principles outlined in the Declaration of Helsinki and was approved by Bioethics Committee of the Medical University of Lodz. All subjects provided written informed consent.

Statistical analysis {#sec3.1}
--------------------

Categorical variables were reported as the number of observations (*N*) and the corresponding percentage (%) and analyzed with the χ^2^ test or χ^2^ test with Yates' adjustment.

Normality of quantitative variables was tested using the Shapiro-Wilk test for normality. Because of the lack of normality for the majority of variables, they were presented as medians with interquartile range. Patients were divided into two subgroups: severe AS and non-severe AS. Differences between groups were analyzed using Student's *t*-test (normal distribution) or Mann-Whitney *U*-test (not normal distribution).

For significant quantitative variables receiver operating characteristic (ROC) curves were drawn and optimal decision thresholds were found using the Youden index. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated. Odds ratios (OR) with 95% confidence interval (CI) were also presented.

Significant variables (*p* \< 0.1) were analyzed using stepwise linear regression models. To assess correlations between sST2 and NT-proBNP with echocardiographic parameters of aortic stenosis severity, Spearman correlation coefficients were used. A *p*-value \< 0.05 was considered statistically significant.

Statistical calculations were performed with Statistica 10 PL (StatSoft Inc., USA) and SPSS v. 21 (SPSS Inc., USA) and R -- project v. 3.0.2 (R Core Team, The R Foundation for Statistical Computing, Vienna, Austria).

Results {#sec4}
=======

The baseline and echocardiographic characteristics of the total cohort and comparison between patients with severe and non-severe AS are shown in [Tables I](#t0001){ref-type="table"} and [II](#t0002){ref-type="table"}. There were 43 (62.32%) patients with severe AS. Univariate stepwise linear regression analysis showed that systolic blood pressure (SBP), LVEDD, LVESD, QRS duration and Sokolow-Lyon index were predictors of severe AS. The multivariate stepwise linear regression models revealed that only systolic blood pressure (SBP), Sokolow-Lyon index and LVEDD were independently associated with severe AS. Results of univariate and multivariate stepwise linear regression models are shown in [Table III](#t0003){ref-type="table"}. Moreover, patients with severe AS had higher values of IVSd and PWd and had a higher incidence of diastolic dysfunction.

###### 

Baseline characteristics of total cohort and comparison between patients with severe aortic stenosis (AS) and non-severe AS. Variables are shown as median values with upper and lower quartiles

  Variables                   Total cohort (*n* = 69)   Severe AS (*n* = 43)   Non-severe AS (*n* = 26)   *P*-value
  --------------------------- ------------------------- ---------------------- -------------------------- -----------
  Age \[years\]               70 (61--77)               70 (61--77)            71.5 (59--77)              0.9802
  Men, *n* (%)                31 (44.93)                                                                  
  BMI \[kg/m²\]               27.9 (25.1--31)           27 (24.7--29.9)        29.7 (26.1--31.1)          0.2702
  SBP \[mm Hg\]               130 (120--140)            130 (120--140)         120 (120--130)             0.0174
  DBP \[mm Hg\]               70 (70--80)               70 (70--80)            75 (60--80)                0.5154
  NYHA class                  3 (2--3)                  3 (2--3)               2 (2--3)                   0.0037
  Heart rate \[bpm\]          70 (65--80)               70 (65--80)            67.5 (60--75)              0.3119
  QRS duration \[ms\]         95.5 (90--100)            90 (82--100)           99 (92--114)               0.0095
  QTc duration \[ms\]         429.5 (408.5--451.5)      421 (400--443)         434 (417--463)             0.0674
  Sokolow-Lyon index \[mm\]   28 (23--36)               33 (25--37)            25 (19--28)                0.0132
  sST2 \[ng/ml\]              0.26 (0.18--0.44)         0.29 (0.17--0.53)      0.26 (0.21--0.44)          0.7851
  NT-proBNP \[pg/ml\]         584 (244--1445)           644 (268.6--1837)      571 (145.2--1207.5)        0.1857
  TC \[mmol/l\]               4.8 (4.1--5.5)            4.6 (4.1--5.3)         4.95 (3.6--5.6)            0.9285
  LDL \[mmol/l\]              2.5 (2.2--3.6)            2.5 (2.3--3.4)         2.75 (1.8--3.7)            0.8434
  HDL \[mmol/l\]              1.31 (1.1--1.59)          1.29 (1.12--1.42)      1.38 (1.03--1.7)           0.6538
  TG \[mmol/l\]               1.32 (0.9--1.58)          1.3 (1.06--1.58)       1.32 (0.74--1.48)          0.5904
  Glucose \[mmol/l\]          5.9 (5.4--6.5)            5.95 (5.4--6.9)        5.8 (5.3--6.4)             0.3667
  BUN \[mg/dl\]               6 (4.9--7.4)              5.7 (4.7--7.25)        6.6 (5.3--7.8)             0.2379
  Creatinine \[μmol/l\]       76.5 (67--84)             75.5 (67--84)          77.5 (67--90)              0.1240
  Bilirubin \[μmol/l\]        11.45 (7.2--15.4)         9.2 (6--15.4)          13.6 (8.6--15.4)           0.4570
  Uric acid \[μmol/l\]        341.5 (303--400)          331 (299--385)         381 (322--415)             0.1921
  Hs-CRP \[mg/dl\]            1.6 (0.8--3.7)            1.6 (0.6--2.9)         2.55 (0.9--7.6)            0.0459
  Sodium \[mmol/l\]           139 (138--141)            139 (138--141)         139 (138--141)             0.5362
  WBC \[10^3^/μl\]            7 (6.3--8.3)              7.1 (5.8--8.6)         6.8 (6.4--8.3)             0.8655
  Hemoglobin \[g/dl\]         14.23 (12.88--15.5)       13.8 (12.6--15.44)     14.84 (13.2--15.68)        0.1507
  Platelets \[10^3^/μl\]      206 (174--255)            208 (167--264)         202 (184--252)             0.9951
  Neutrophils (%)             61 (55--66.6)             64.3 (56--67)          57.6 (54.6--63)            0.0807

BMI -- body mass index, BUN -- blood urea nitrogen, DBP -- diastolic blood pressure, HDL -- high-density lipoprotein, HF -- heart failure, hs-CRP -- high-sensitivity C-reactive protein, hs-TnT -- high-sensitivity troponin T, NT-proBNP -- *N*-terminal pro-B- type natriuretic peptide, NYHA -- New York Heart Association, SBP -- systolic blood pressure, sST2 -- soluble ST2, TC -- total cholesterol, TG -- triglycerides, WBC -- white blood cells.

###### 

Echocardiographic characteristics of total cohort and comparison between patients with severe aortic stenosis (AS) and non-severe AS. Variables are shown as median values with upper and lower quartiles

  Variables                        Total cohort (*n* = 69)   Severe AS (*n* = 43)   Non-severe AS (*n* = 26)   *P*-value
  -------------------------------- ------------------------- ---------------------- -------------------------- -----------
  AVA \[cm^2^\]                    0.8 (0.6--1.3)            0.7 (0.53--0.8)        1.4 (1.25--1.68)           \< 0.0001
  MPG \[mm Hg\]                    42 (24--50)               45 (42--56)            20 (13--28)                \< 0.0001
  Peak aortic velocity \[m/s\]     4.1 (3.27--4.6)           4.45 (4.2--5.12)       3 (2.5--3.5)               \< 0.0001
  LVESD \[cm\]                     3.1 (2.8--3.6)            3 (2.8--3.3)           3.6 (3.05--3.95)           0.0152
  LVEDD \[cm\]                     4.8 (4.5--5.3)            4.8 (4.4--5.1)         5.1 (4.7--5.7)             0.0126
  LVEF (%)                         61 (57--65)               62 (58--66)            59 (51.5--62.5)            0.0003
  IVSd \[cm\]                      1.3 (1.2--1.4)            1.3 (1.3--1.4)         1.2 (1--1.35)              0.0290
  IVSs \[cm\]                      1.7 (1.6--1.9)            1.8 (1.65--1.9)        1.7 (1.5--1.9)             0.3642
  PWd \[cm\]                       1.2 (1.1--1.3)            1.25 (1.2--1.3)        1.05 (1--1.13)             0.0004
  PWs \[cm\]                       1.7 (1.6--1.8)            1.7 (1.6--1.8)         1.6 (1.4--1.8)             0.2909
  Diastolic dysfunction, *n* (%)   32 (46.38)                25 (58.14)             7 (26.92)                  0.0545

Diastolic dysfunction includes impaired relaxation, pseudo-normal filling, and restrictive filling, and was assessed according to transmitral inflow pattern (E/A ratio, deceleration time) or pulsed-wave TDI mean e' velocity. AVA -- aortic valve area, IVSd -- interventricular septal end-diastole, IVSs -- interventricular septal end-systole, LVEDD -- left ventricular end-diastolic diameter, LVEF -- left ventricular ejection fraction, LVESD -- left ventricular end-systolic diameter, MPG -- mean pressure gradient, PWd -- posterior wall end-diastole, PWs -- posterior wall end-systole.

###### 

Univariate and multivariate stepwise linear regression analysis for the prediction of severe aortic stenosis

  Variables                   Univariate analysis    Multivariate analysis                           
  --------------------------- ---------------------- ----------------------- ----------------------- -------
  SBP \[mm Hg\]               1.047 (1.006--1.089)   0.023                   1.081 (1.001--1.168)    0.015
  QRS duration \[ms\]         0.971 (0.944--1.000)   0.047                   0.964 (0.907--1.026)    0.332
  Sokolow-Lyon index \[mm\]   1.082 (1.014--1.154)   0.018                   1.106 (0.981--1.247)    0.043
  LVESD \[cm\]                0.358 (0.131--0.975)   0.045                   1.143 (0.126--10.376)   0.817
  LVEDD \[cm\]                0.289 (0.102--0.823)   0.020                   0.108 (0.008--1.462)    0.042
  Neutrophils (%)             1.051 (0.978--1.130)   0.175                   1.045 (0.921--1.186)    0.506

LVEDD -- left ventricular end-diastolic diameter, LVESD -- left ventricular end-systolic diameter, SBP -- systolic blood pressure.

For variables that were significantly associated with the presence of severe AS, receiver operating characteristic (ROC) curves were drawn and optimal decision thresholds were found using the Youden index. Sensitivity, specificity, positive predictive value, and negative predictive value were calculated. Odds ratios (ORs) with 95% confidence intervals (CIs) were also presented ([Tab. IV](#t0004){ref-type="table"}). Spearman correlation coefficients analysis showed no correlations between sST2 levels and a mild to moderate correlation between NT-proBNP concentration and parameters of AS severity ([Tab. V](#t0005){ref-type="table"}). Moreover, levels of NT-proBNP (*p* = 0.1857) and sST2 (*p* = 0.7851) did not differentiate patients according to severity of AS.

###### 

Results of receiver operating characteristic (ROC) curve analyses of significant variables for predicting severe aortic stenosis

  ----------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                   Cut-off point   AUC (95% CI)            Sensitivity (%)   Specificity (%)   PPV (%)   NPV (%)   OR (95% CI)
  --------------------------- --------------- ----------------------- ----------------- ----------------- --------- --------- ------------------------
  SBP \[mm Hg\]               ≥ 132.5         0.665 (0.534--0.797)\   44.2              84.6              82.6      47.8      4.354 (1.281--14.802)\
                                              *p* = 0.022                                                                     *p* = 0.0139

  LVEDD \[cm\]                ≤ 5.35          0.698 (0.532--0.863)\   90.0              41.2              78.3      63.6      6.300 (1.532--25.914)\
                                              *p* = 0.022                                                                     *p* = 0.0064

  Sokolow-Lyon Index \[mm\]   ≥ 30.5          0.697 (0.560--0.835)\   58.5              80.0              82.8      54.1      5.647 (1.770--18.020)\
                                              *p* = 0.008                                                                     *p* = 0.0022
  ----------------------------------------------------------------------------------------------------------------------------------------------------

AUC -- area under the curve, CI -- confidence interval, HR -- heart rate, LVEDD -- left ventricular end-diastolic diameter, OR -- odds ratio, PPV -- positive predictive value, SBP -- systolic blood pressure.

###### 

Spearman rank order correlations between sST2 and NT-proBNP levels and parameters of aortic stenosis severity

  Parametersof AS severity   sST2       NT-proBNP              
  -------------------------- ---------- ----------- ---------- --------
  AVA                        0.0002     0.9986      --0.3462   0.0096
  MPG                        --0.0555   0.6579      0.2621     0.0413
  Peak aortic velocity       --0.0092   0.9432      0.2665     0.0413

AS -- aortic stenosis, AVA -- aortic valve area, MPG -- mean pressure gradient.

Discussion {#sec5}
==========

Our study showed that in the study population with degenerative AS and preserved LVEF the concentrations of the biomarkers NT-proBNP and sST2 cannot be used to differentiate patients according to the severity of this valvular heart disease. In the available literature there are no studies evaluating the diagnostic value of both biomarkers in patients with AS and preserved LVEF.

Sawada *et al.* revealed that the Il-33/ST2 system may be involved in the pathophysiology of AS \[[@cit0010]\]. They observed that IL-33 and sST2 were expressed in human aortic valves in patients with stenosis as well as regurgitation, there were no differences in expression levels of Il-33, but sST2 expression levels were up-regulated in the group with AS \[[@cit0010]\]. Moreover, Bartunek *et al.* reported that serum sST2 levels were significantly higher in patients with AS compared to the healthy control group. However, they postulated that sST2 is not produced mainly in the myocardium, but vascular endothelial cells are the major source of increased sST2 and increased left ventricular end-diastolic pressure is a predominant hemodynamic factor of sST2 production \[[@cit0011]\]. Lancellotti *et al.* demonstrated in patients with AS and preserved LVEF that sST2 levels were related to left atrial size, LV hypertrophy, severity of AS and LV systolic function. Investigators revealed that sST2 protein is also a good prognostic marker in AS. In symptomatic patients it was correlated with symptomatic status assessed using NYHA functional class, while in asymptomatic patients sST2 was predictive of symptom-free survival, development of symptoms and aortic valve replacement (AVR) \[[@cit0012]\]. Predictive value of sST2 protein was confirmed in a study of 345 patients with severe AS treated invasively: surgical AVR or transcatheter AVR. sST2 was associated with outcome in both groups; there was 1.7-fold higher risk of postoperative mortality in patients with elevated levels of sST2 *p* \< 0.001). Moreover, a multiple biomarker approach including sST2, NT-proBNP and growth differentiation factor 15 (GDF-15) improved risk stratification in comparison to the Society of Thoracic Surgeons (STS) risk score alone \[[@cit0013]\].

In our study in patients with AS and preserved LVEF we established a correlation between NT-proBNP levels and parameters of AS severity: maximum jet velocity, mean transvalvular pressure gradient and AVA ([Tab. V](#t0005){ref-type="table"}). Our results are consistent with previous reports \[[@cit0014], [@cit0015]\]. Despite the correlation with parameters of AS severity, in our research NT-proBNP did not differentiate patients according to AS severity: severe vs. non-severe AS. NT-proBNP is also a recognized predictor of cardiovascular events and perioperative risk in a population with aortic stenosis \[[@cit0004], [@cit0015]\], which was reflected in the current guidelines of the European Society of Cardiology on the management of valvular heart disease \[[@cit0001]\].

Bartunek *et al.* showed that sST2 and NT-proBNP levels correlate with diastolic load (left ventricular end-diastolic pressure) irrespective of left ventricular systolic function \[[@cit0011]\]. In our study, patients with severe AS had significantly higher values of parameters of left ventricular hypertrophy (IVSd, PWd), but there was no significant difference in occurrence of diastolic dysfunction between the population with severe and non-severe AS (*p* = 0.0545). Probably the lack of statistical significance in occurrence of diastolic dysfunction is caused by the relatively small study population. This may explain the lack of difference in the concentration of tested biomarkers.

In our study Sokolow-Lyon index ≥ 30.5 mm, SBP ≥ 132.5 mm Hg and LVEDD ≤ 5.35 cm were independently associated with severe AS. The Sokolow-Lyon index is a recognized prognostic factor for the presence of cardiac hypertrophy, regardless of etiology, including left ventricular hypertrophy (LVH) in patients with AS \[[@cit0016]\]. However, ECG criteria of LVH including the Sokolow-Lyon index do not correlate well with echocardiographic parameters of LVH \[[@cit0017], [@cit0018]\]. The Sokolow-Lyon index value lower than 35 mm as a predictor of severe AS obtained in our study may be the outcome of "the relative voltage deficit" hypothesis, a deviation connected with changes in electrical features of the myocardium in LVH \[[@cit0019]\]. In the non-severe AS population, the Sokolow-Lyon index was demonstrated to be a risk factor of cardiovascular mortality and morbidity independent of other clinical and echocardiographic variables \[[@cit0020]\]. We hypothesize that assessment of the Sokolow-Lyon index in the resting ECG could be a low-cost and widely available screening tool for severe AS, mainly in asymptomatic and oligosymptomatic patients.

In our study there was a significant association between SBP with a cut-off point ≥ 132.5 mm Hg and presence of severe AS. High prevalence of 30--40% of the concomitant hypertension in patients with AS has been described previously \[[@cit0021]\]. Moreover, in patients with AS and preserved LVEF, systolic hypertension and increased pulse pressure (defined as SBP-DBP) suggest that the degenerative process is not limited to the aortic valve, but also involves the vascular system distal to the valve \[[@cit0022]\].

In the studied population LVEDD ≤ 5.35 cm was independently associated with severe AS. According to LaPlace's law, LV pressure overload in AS leads to LV hypertrophy to maintain LV systolic function followed by adverse cardiac remodeling and impaired systolic function \[[@cit0023]\]. We included patients with preserved LVEF, which reflects the population before the occurrence of maladaptive cardiac remodeling. In the literature, there are reports of smaller LV cavities in patients with different pathophysiological forms of AS: patients without LV hypertrophy \[[@cit0024]\] and paradoxical low-flow, low-gradient severe AS \[[@cit0025]\]. However, further studies are needed to elucidate these issues.

This study has several limitations. This is a single-center study, and the number of patients in the study was relatively small. We assessed LVH only with the Sokolow-Lyon index; other algorithms including the Cornel voltage index and the Romhilt-Estes method were not used. We studied only patients with preserved LVEF, so the results could not be extrapolated to the population with reduced LVEF. We assessed only parameters of left ventricle wall thickness, without estimation of left ventricular mass.

Conclusions {#sec6}
===========

In the study population with degenerative AS and preserved left ventricular systolic function the concentrations of the biomarkers NT-proBNP and sST2 cannot be used to differentiate patients according to the severity of this valvular heart disease despite the correlation of NT-proBNP levels with parameters of AS severity.
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